ArticleGene therapy2001
Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats.
Article in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 76 citations in OpenAlex.
- Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity.Human vaccines & immunotherapeutics · 2020Article
- Induction of a local muscular dystrophy using electroporation in vivo: an easy tool for screening therapeutics.Scientific reports · 2020Article
- A Critical Review of Electroporation as A Plasmid Delivery System in Mouse Skeletal Muscle.International journal of molecular sciences · 2019Review
- Electroporation-mediated gene delivery.Advances in genetics · 2015Article
- Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression.Experimental & molecular medicine · 2012Article
- Minimal doses of a sequence-optimized transgene mediate high-level and long-term EPO expression in vivo: challenging CpG-free gene design.Gene therapy · 2011Article
- Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment.Genetic vaccines and therapy · 2008Article
- Gene expression profiles in skeletal muscle after gene electrotransfer.BMC molecular biology · 2007Article
- Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation.Gene therapy · 2007Article
- Progress toward a nonviral gene therapy protocol for the treatment of anemia.Human gene therapy · 2007Article
- Gene therapy targeting kidney diseases: routes and vehicles.Clinical and experimental nephrology · 2006Review
- DNA electrotransfer: its principles and an updated review of its therapeutic applications.Gene therapy · 2004Review
- Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice.Laboratory investigation; a journal of technical methods and pathology · 2004Article
- Rat kidney-targeted naked plasmid DNA transfer by retrograde injection into the renal vein.Molecular biotechnology · 2004Article
- Rat liver-targeted naked plasmid DNA transfer by tail vein injection.Molecular biotechnology · 2004Article
- Hydrodynamics-based delivery of the viral interleukin-10 gene suppresses experimental crescentic glomerulonephritis in Wistar-Kyoto rats.Gene therapy · 2003Article
- Non-viral gene delivery in skeletal muscle: a protein factory.Gene therapy · 2003Review
- Skin-targeted gene transfer using in vivo electroporation.Gene therapy · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anemia associated with chronic renal failure is one of the best target diseases for erythropoietin (Epo) gene transfer. We previously reported a short-term (1 month) study of continuous rat Epo delivery by muscle-targeted gene transfer of plasmid DNA expressing rat Epo (pCAGGS-Epo) using in vivo electroporation in normal rats. Here, we performed a long-term pharmacokinetic study of continuous Epo delivery by this method in normal rats and uremic five-sixths nephrectomized rats. In normal rats, Epo gene expression and sufficient erythropoiesis occurred with Epo gene transfer in a dose-dependent manner, and persisted for at least 11 weeks. Repeated administration of the plasmid DNA effectively produced erythropoiesis. Similar erythropoiesis was observed in the uremic rats, and persisted for more than 15 weeks. Both normal and uremic rats showed a significant decrease in platelet count. Moreover, the uremic rats showed Epo-induced hypertension, which is the major side-effect of recombinant human Epo. These results demonstrate that muscle-targeted pCAGGS-Epo transfer by in vivo electroporation is a useful procedure for the long-term continuous delivery of Epo in both normal and uremic rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.